DPP4 and type 2 diabetes mellitus: The twenty-first century has seen the approval of a number of new drug classes for treating T2DM, including the SGLT2 inhibitors, as well as the GLP-1R agonists and DPP-4 inhibitors, often collectively referred to as incretin-based therapies.